The study directly compares Zepbound and Wogovy to obtain weight loss results

Peop loss medications continue to grow in popularity as a tool against obesity, but are some more effective than others?

The question was explored in a new study published this month at the New England Journal of Medicine.

The researchers compared the safety and efficacy of the Tirzepatido (Zepbound brand) and the Semaglutida (Wegovy brand) in a 72 -week clinical trial.

Weight loss medications can also benefit the common medical problem, the study finds

The randomized and controlled trial, called Surmount-5, included 751 people throughout the United States and Puerto Rico who had obesity but not type 2 diabetes.

“Doctors, insurance companies and patients always ask: ‘What medicine is more effective?'” Said Dr. Louis Aronne, director of the Integral Weight Control Center and Weill’s metabolic research professor at Weill Cornell Medicine, in the statement. “This study allowed us to make a direct comparison.”

“The results are consistent with, in fact, almost identical to, what we have seen in the trials in which these medications were evaluated independently,” added Aronne, who was the main researcher in the essay.

The study found that the tirzepatido achieved greater weight loss, with the participants who spilled around 50 pounds (20.2% of their body weight).

“Doctors, insurance companies and patients always ask: ‘What medication is more effective?'”

The group that took Semaglutida lost an average of 33 pounds or 13.7% of its basal weight, according to a press release that summarizes the study result.

In general, 32% of people who take Tirzepaturo lost at least 25% of their body weight; Semaglutidas users lost around 16%.

Weight loss, diabetes medications can cause changes in mood: what to know about the side effects of behavior

Tirzepatide users also reported a “greater reduction in the circumference of the waist” than those of the semaglutida.

The probable reason for the greatest effectiveness of the tirzepatida is that it uses a “dual action mechanism,” according to Aronne.

“While the semaglutido works by activating receptors for a hormone called peptide similar to glucagon 1, or LPG-1, the tirzepatida mimics not only LPG-1, but also an additional hormone, glucose-dependent insulinotropic peptide (GIP),” said release.

“Together, these actions reduce hunger, reduce blood glucose levels and affect the metabolism of fat cells.”

The impact of medicines for weight loss on cancer risk in a new study

Additional trials actively explore if the tirzepatido also reduces the risk of heart attack and stroke, a benefit that has been related to the semaglutida.

The study was led by a Weill Cornell Medicine and Newyork-Presbyterian researcher. It was also carried out with the Faculty of Medicine of the University of Texas McGovern, the David Geffen School of Medicine of the University of California, Los Angeles, the University College Dublin and Eli Lilly (Zepbound manufacturer).

All participants received guidance on nutrition and exercise.

The informed side effects were very similar for the two drugs, with 44% of the people who experienced nausea and 25% with abdominal pain.

PEOPLE LOSS MEDICINES TO GET A surprising support from the World Health Giant

Dr. Ada London, MD, a primary care doctor of Obesity and Internal Medicine certified by the Board and Internal Medicine, with a luxury care, a virtual health platform that offers primary care services, therapy and weight management, said it was not surprised by the study findings.

“The results are consistent with the previous essays, confirming Tirzepatide’s advantage over the Single LPG-1 action of Semaglutide,” London said, based in New York City, News Digital.

Beyond weight loss, semaglutida has also shown potential benefits for cardiovascular health, sleep apnea and kidney disease, he said.

“These findings highlight the need for continuous investigation to understand the broader health impacts of Tirzepatide,” he said. “It is encouraging to see current studies exploring the entire potential of GLP-1 medicines beyond weight control.”

London said that these treatments can come with side effects.

It was discovered that semaglutida has a shocking benefit for patients with liver disease in a new study

“Most people in these medications only report mild symptoms, but some have experienced more serious reactions, such as pancreatitis,” News Digital told News.

“This underlines the importance of reviewing your medical history and discussing any concern with your medical care provider.”

Potential limitations

The study had some limitations, mainly that it was not an blinding analysis and the participants knew what medicine they were receiving. This could introduce a certain level of bias, the researchers recognized.

London said that while the studies of the study are “promising”, it was funded by Eli Lilly, the Zepbound manufacturer.

“This can ask questions about possible conflicts of interest,” he said. “In addition, the open design and duration of 72 weeks can limit objectivity and long -term vision.”

Although the study mainly analyzed the impact of medicines, experts agreed that there are other factors that play a role in successful weight control.

“Weight loss is biological, but it is also emotional, and the support of the complete person can make the difference between short -term results and sustainable health,” Dr. Rekha Kumar, a medical director of the weight care program and an endocrinologist in exercise in New York city, told News News News.

Click here to get the News application

Kumar emphasized the importance of working with a doctor to choose a weight loss medication that coincides with the patient’s personal and state of health.

“Both Wegovy and Zepbound have demonstrated a clinically significant weight reduction.”

“For example, if a patient has a fatty liver, we will choose the GLP-1 that shows that it works best for liver disease,” he said.

Looking to the future, researchers plan to investigate new versions of weight loss, including the undatrupted, which imitates GLP-1, GIP and glucagon hormones, according to the statement.

Click here to register in our health newsletter

“Although drugs such as Tirzepatide and Semaglutida work very well, better than anything we have seen, we still have people who do not respond to them,” said Aronne.

“Then, in the future, we want to keep trying to do better.”

A spokesman for Novo Nordisk, the company that manufactures Wegovy (Semaglutide), sent a statement to News Digital.

“In the respective programs of clinical trials and in Surmit-5, both Wogovy and Zepbound have demonstrated a clinically significant weight reduction,” the company said. “It is important to recognize that the integral management of obesity goes beyond weight reduction.”

For more health articles, visit www.Newsnews.com/health

The spokesman also pointed out that in a previous trial, obese or overweight adults and who took cursed along with the diet and exercise lost an average of 15.2% of their weight (~ 35 pounds) in the two -year mark, compared to 2.6% (~ 6 pounds) for patients who take a placebo.